RxDoctor Payments Data

Megan Jagosky, MD

Internal Medicine · Charlotte, NCNPI 1730590050

Payments from drug & device makers

$49,926in general payments, 2019–2025

Across 12 payments — averaging $4160.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$44K
  • EMD Serono, Inc.$3K
  • Springworks Therapeutics, Inc.$2K
  • Deciphera Pharmaceuticals Inc.$500
  • Incyte Corporation$240
  • Aadi Bioscience, Inc.$105
  • plus $228 from 3 others

What the payments were for

  • Consulting fees$4,68878%
  • Speaking & faculty fees$5008%
  • Food & beverage$72412%
  • Education$761%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,926 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,366
Medicare patients
123
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OgsiveoNirogacestat Hydrobromide11$298,699
CabometyxCabozantinib S-Malate12$287,461
Lenalidomide13$213,936
AlecensaAlectinib Hcl12$200,843
EliquisApixaban41$24,053
Sunitinib Malate12$17,208
XareltoRivaroxaban30$16,018
Letrozole36$1,126
Potassium Chloride15$506
Ondansetron Hcl33$356
Dexamethasone15$309
Anastrozole28$300
Tramadol Hcl17$226
Prednisone44$186
Acyclovir17$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Springworks Therapeutics, Inc.Ogsiveo$2,065$298,69911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →